Welcome to the UPF Digital Repository

Iron replacement and redox balance in non-anemic and mildly anemic iron deficiency COPD patients: insights from a clinical trial

Show simple item record

dc.contributor.author Pérez-Peiró, Maria
dc.contributor.author Martín-Ontiyuelo, Clara
dc.contributor.author Rodó-Pin, Anna
dc.contributor.author Piccari, Lucilla
dc.contributor.author Admetlló Papiol, Mireia
dc.contributor.author Duran Jordà, Xavier, 1974-
dc.contributor.author Rodríguez Chiaradia, Diego Agustín
dc.contributor.author Barreiro Portela, Esther
dc.date.accessioned 2022-05-19T07:15:37Z
dc.date.available 2022-05-19T07:15:37Z
dc.date.issued 2021
dc.identifier.citation Pérez-Peiró M, Martín-Ontiyuelo C, Rodó-Pi A, Piccari L, Admetlló M, Durán X, et al. Iron replacement and redox balance in non-anemic and mildly anemic iron deficiency COPD patients: insights from a clinical trial. Biomedicines. 2021 Sep 10; 9(9): 1191. DOI: 10.3390/biomedicines9091191
dc.identifier.issn 2227-9059
dc.identifier.uri http://hdl.handle.net/10230/53164
dc.description.abstract In COPD patients, non-anemic iron deficiency (NAID) is a common systemic manifestation. We hypothesized that in COPD patients with NAID, iron therapy may improve systemic oxidative stress. The FACE (Ferinject assessment in patients with COPD and iron deficiency to improve exercise tolerance) study was a single-blind, unicentric, parallel-group, placebo-controlled clinical trial (trial registry: 2016-001238-89). Sixty-six patients were enrolled (randomization 2:1): iron arm, n = 44 and placebo arm, n = 22, with similar clinical characteristics. Serum levels of 3-nitrotyrosine, MDA-protein adducts, and reactive carbonyls, catalase, superoxide dismutase (SOD), glutathione, Trolox equivalent antioxidant capacity (TEAC), and iron metabolism biomarkers were quantified in both groups. In the iron-treated patients compared to placebo, MDA-protein adducts and 3-nitrotyrosine serum levels significantly declined, while those of GSH increased and iron metabolism parameters significantly improved. Hepcidin was associated with iron status parameters. This randomized clinical trial evidenced that iron replacement elicited a decline in serum oxidative stress markers along with an improvement in GSH levels in patients with stable severe COPD. Hepcidin may be a surrogate biomarker of iron status and metabolism in patients with chronic respiratory diseases. These findings have potential clinical implications in the management of patients with severe COPD.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.rights Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Iron replacement and redox balance in non-anemic and mildly anemic iron deficiency COPD patients: insights from a clinical trial
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/biomedicines9091191
dc.subject.keyword Iron metabolism
dc.subject.keyword Iron replacement as a therapeutic opportunity
dc.subject.keyword Non-anemic iron deficient (NAID) COPD patients
dc.subject.keyword Pathophysiological mechanisms
dc.subject.keyword Redox balance
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking